Novo Seeds Portfolio Company HepaRegeniX GmbH secures Series B Financing in excess of EUR 11 Million

The proceeds will be used to advance the first MKK4 inhibitor into clinical development later in 2020

Novo Seeds, the early stage investment and company creation team of Novo Holdings, today announced that its portfolio company HepaRegeniX GmbH, a preclinical stage company developing a novel therapy for the treatment of acute and chronic liver diseases has successfully closed a Series B financing round in excess of €11 million.

Read more 

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...